Halozyme Therapeutics (HALO) Cash Flow Statement

Click line-items for a historical chart and %

Operating activities:
Net loss	-75.64M
Adjustments to reconcile net loss to net cash used in operating activities:
Share-based compensation	18.84M
Depreciation and amortization	1.77M
(Gain) loss on disposal of equipment
Changes in operating assets and liabilities:
Accounts receivable	14.73M
Inventory	-3.36M
Prepaid expenses and other assets	1.09M
Accounts payable and accrued expenses	-1.4M
Deferred rent
Deferred revenue	-2.48M
Net cash used in operating activities
Investing activities:
Purchases of property and equipment	-2.69M
Net cash used in investing activities
Financing activities:
Proceeds from exercise of stock options, net
Net cash provided by financing activities
Net decrease in cash and cash equivalents	17.92M
Cash and cash equivalents at beginning of period	43.29M
Cash and cash equivalents at end of period	61.21M
Supplemental disclosure of non-cash investing and financing activities:
Accounts payable for purchases of property and equipment

Entities mentioned with HALO